Loading clinical trials...

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Multicenter, Randomized, Double-blind, Placebo-controlled, Single-dose Phase 2 Study of the Safety and Efficacy of JTM201 (Botulinum Toxin Type A) to Treat Moderate or Severe Glabellar Lines

NCT06246552•Jetema USA Inc.

View on ClinicalTrials.gov

Summary

This is Multicenter, Randomized, Double-blind, Placebo-controlled, Single-dose Study to evaluate Safety and Efficacy of JTM201 in patients with Moderate or Severe Glabellar Lines

Detailed Description

This is Multicenter, Randomized, Double-blind, Placebo-controlled, Single-dose Study to evaluate Safety and Efficacy of JTM201 in patients with Moderate or Severe Glabellar Lines. Treatment period is 180 days and evaluation of the safety is the primary endpoint

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects ≥18 years of age based on the date of the written informed consent form.
•Subject is able to provide written informed consent and comply with study procedures.
•Subject has moderate or severe glabellar lines on maximum frown as assessed by the investigator and subject using the GLS (score of 2 or 3).

Exclusion Criteria

•Previous insertion of permanent material in the glabellar area including the forehead.
•Planned treatment with botulinum toxin of any serotype in any other body region during the study period.
•Pregnant or breastfeeding (directly or via pump); or planning to become pregnant during the study.
•Known allergy or hypersensitivity to botulinum toxin or product excipients.
•Participation in another interventional clinical study ≤30 days of Visit 1: Screening.
•Planning to donate, bank, or retrieve eggs (ova, oocytes) or donate sperm during the study.

Locations (1)

Ablon Skin Institute & Research Center

Manhattan Beach, California, United States

Key Dates

Start Date

October 26, 2024

Primary Completion Date

June 5, 2025

Completion Date

June 5, 2025

Last Updated

August 29, 2025

Enrollment

480

ACTUAL participants

Conditions

Glabellar Lines

Interventions

JTM201

BIOLOGICAL

Placebo

BIOLOGICAL

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

NCT06481475

Moderate to Severe Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE2

A Study to Evaluate AI-09 In Participants With Glabellar Lines

NCT07321834

Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE3

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Inclusion Criteria

Exclusion Criteria

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

A Study to Evaluate AI-09 In Participants With Glabellar Lines

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines